🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Extremely honored to receive this award! Many thanks to Fabrice Lucien, PhD Lucien Lab Yohan J Kim Mayo Clinic Urology for their support

First author, when manuscript gets accepted with minor revisions

Congrats ZorkoNK for delivering a state-of-the-art lecture about NK cell therapeutics at the Banff GU Conference 2022

Extremely honored to announce that my very first ASCO abstract has been accepted for an oral presentation as part of a clinical science symposium! I am very grateful for the mentorship and guidance of Emmanuel Antonarakis. Thank you OOO for making this happen!! #ASCO23

Effect of germline mutations on somatic alteration landscapes in BRCA-associated cancers [2023] Ali Arafa et al. Emmanuel Antonarakis #ASCO23 Abst #10509 meetings.asco.org/abstracts-pres… #PrecisionMedicine #geneticcounselors University of Minnesota Johns Hopkins Kimmel Cancer Center OOO

Abstr 10509: Largest study examining the somatic genomic landscape of tumors developing in germline HRR mutation carriers versus sporadic cancers. Congrats Ali Arafa for your first ASCO Oral presentation. Thanks to OOO for this rich data set. meetings.asco.org/abstracts-pres…

Stoked for our ASCO poster showing NK cell infiltration and survival benefit across numerous solid tumors. NK cells are coming for you prostate cancer!

Congrats Ali Arafa for delivering your first Oral ASCO Abstract. Your impactful study shows that germline mutations clearly influence somatic mutation landscapes in BRCA-associated cancers. ascopubs.org/doi/abs/10.120…

I'm thrilled to share that I have been awarded an American Cancer Society Postdoctoral Fellowship for my prostate cancer research. Many thanks to the prostate cancer team Justin M. Drake, PhD Emmanuel Antonarakis Scott Dehm and UMN Pharmacology and MPaT for their invaluable support.

Congratulations to new American Cancer Society postdoctoral fellow, Ali Arafa. His project addresses an important clinical problem - identifying biomarkers of response to Pluvicto among men receiving treatment for castration resistant metastatic prostate cancer. Thank you and good luck!

Our multi-omics study highlights the unique biology of AMPC, a potential precursor to NEPC, with implications for early therapeutic targeting. FOXA1 and OTX2 may play crucial roles! Justin M. Drake, PhD Emmanuel Antonarakis UMN Pharmacology and MPaT Masonic Cancer Center, University of Minnesota

Congratulations Ali Arafa on developing the first prognostic blood-based PROTEOMIC biomarker for 177Lu-PSMA-617 efficacy, presented at ASCO ‘25. Masonic Cancer Center, University of Minnesota University of Minnesota meetings.asco.org/abstracts-pres…

Excited to share our prostate cancer proteomics work, initially presented at #ASCO25, is now featured on VuMedi! Grateful for the chance to share how liquid biopsy biomarkers may help shape the future of personalized therapy. Masonic Cancer Center, University of Minnesota UMN Pharmacology and MPaT vumedi.com/video/ascor-20…